# Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

> **NCT05361954** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Cancer
- Cancer of Pancreas
- Sarcoma
- Hepatic Metastasis
- Solid Tumor

## Interventions

- **DRUG:** STI-1386

## Key facts

- **NCT ID:** NCT05361954
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08
- **Primary completion:** 2026-10
- **Final completion:** 2027-02
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361954, "Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT05361954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*